BioCentury | Mar 31, 2021
Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

...field as a whole By Karen Tkach Tuzman, Senior Editor The FTC’s 4-0 vote to challenge Illumina’s...
...vertical integration is the U.S. Federal Trade Commission’s concern that the next-generation sequencing (NGS) business of Illumina Inc....
...Illumina said it “intends to pursue all legal options in order to complete the acquisition.” Illumina...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Farallon Capital, Perceptive Advisors, funds and accounts managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc....
BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...cell therapies for viral diseases, is effective May 17.Jay Flatley is stepping down as chairman of Illumina Inc....
...and Robert Kiss from VP to SVP of process and analytical development. Gunjan Ohri DCVC Bio Section 32 AlloVir Inc. Illumina Inc. SpringWorks...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

...contains tens of thousands of pathogen sequences. With Illumina Inc....
...partners developed to detect hundreds of respiratory pathogens.Illumina...
...it is implemented.” Karen Tkach Tuzman IDbyDNA Inc. Ginkgo Bioworks Inc. In-Q-Tel Illumina Inc. covid19 covid-19 cov19dx ngs sequencing surveillance...
BioCentury | Feb 9, 2021
Finance

Illumina unveils latest entrants to accelerator in SF, U.K.

...nine more start-ups to the stable of genomics newcos residing at its Illumina Accelerator.On Monday, Illumina Inc....
...adjacent to Illumina’s campuses in San Francisco and Cambridge. In addition, Amanda Cashin, global head of Illumina...
...Health Ltd.Illumina is accepting applications for its next global cycle; they are due March 1. Stephen Hansen Illumina Inc. bee2021...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...infectious disease company Vir Biotechnology Inc. (NASDAQ:VIR); early cancer detection company Grail Inc., acquired by Illumina Inc....
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

...not the gene that encodes the spike protein.Illumina Inc....
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...test next quarter, following its $8 billion takeout in September by the company’s originator and investor, Illumina Inc....
...OrbiMed, the series A round had participation from existing investors including Menlo Ventures, Samsara Biocapital, Illumina...
...company raised a $5.5 million seed financing led by Menlo Ventures and including Samsara BioCapital, Illumina...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

...of enzymes, is a professor at the California Institute of Technology and a director of Illumina Inc....
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...by its $2.2 billion takeout by Exact Sciences Corp. (NASDAQ:EXAS) in October, Grail Inc.’s takeout by Illumina Inc....
Items per page:
1 - 10 of 835
BioCentury | Mar 31, 2021
Regulation

FTC challenge to Illumina’s Grail acquisition focused on potential harms from its supplier role

...field as a whole By Karen Tkach Tuzman, Senior Editor The FTC’s 4-0 vote to challenge Illumina’s...
...vertical integration is the U.S. Federal Trade Commission’s concern that the next-generation sequencing (NGS) business of Illumina Inc....
...Illumina said it “intends to pursue all legal options in order to complete the acquisition.” Illumina...
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Farallon Capital, Perceptive Advisors, funds and accounts managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc....
BioCentury | Mar 23, 2021
Management Tracks

Brainard to succeed Hallal as AlloVir CEO; plus Illumina, NeoGenomics, Nordic Nanovector, Abeona, Delix and more

...cell therapies for viral diseases, is effective May 17.Jay Flatley is stepping down as chairman of Illumina Inc....
...and Robert Kiss from VP to SVP of process and analytical development. Gunjan Ohri DCVC Bio Section 32 AlloVir Inc. Illumina Inc. SpringWorks...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

...contains tens of thousands of pathogen sequences. With Illumina Inc....
...partners developed to detect hundreds of respiratory pathogens.Illumina...
...it is implemented.” Karen Tkach Tuzman IDbyDNA Inc. Ginkgo Bioworks Inc. In-Q-Tel Illumina Inc. covid19 covid-19 cov19dx ngs sequencing surveillance...
BioCentury | Feb 9, 2021
Finance

Illumina unveils latest entrants to accelerator in SF, U.K.

...nine more start-ups to the stable of genomics newcos residing at its Illumina Accelerator.On Monday, Illumina Inc....
...adjacent to Illumina’s campuses in San Francisco and Cambridge. In addition, Amanda Cashin, global head of Illumina...
...Health Ltd.Illumina is accepting applications for its next global cycle; they are due March 1. Stephen Hansen Illumina Inc. bee2021...
BioCentury | Jan 28, 2021
Finance

$1.9B fund gives Arch flexibility for more megarounds

...infectious disease company Vir Biotechnology Inc. (NASDAQ:VIR); early cancer detection company Grail Inc., acquired by Illumina Inc....
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

...not the gene that encodes the spike protein.Illumina Inc....
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...test next quarter, following its $8 billion takeout in September by the company’s originator and investor, Illumina Inc....
...OrbiMed, the series A round had participation from existing investors including Menlo Ventures, Samsara Biocapital, Illumina...
...company raised a $5.5 million seed financing led by Menlo Ventures and including Samsara BioCapital, Illumina...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

...of enzymes, is a professor at the California Institute of Technology and a director of Illumina Inc....
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...by its $2.2 billion takeout by Exact Sciences Corp. (NASDAQ:EXAS) in October, Grail Inc.’s takeout by Illumina Inc....
Items per page:
1 - 10 of 835